logo

COVID-19: Drugs in Development

Share

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
Arcturus Therapeutics Ltd.
(ARCT)
ARCT-154 and ARCT-165 Covid-19 Vaccines
On Aug. 3, 20121, ARCT-154 and ARCT-165, STARR mRNA Vaccines targeting SARS-CoV-2 Variants of concern, given clearance to move into Phase 1/2 study in Singapore
-
-
08/04/2021
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ)
BIOKANGTAI COVID-19 Vaccine
-- Approved in China for emergency use on May 14, 2021
-- Phase 3 trial initiated in Malaysia on Jun.21, 2021
-- On Aug.2, 2021, received approval in the Philippines to launch phase 3 trial
-- Seeking to launch clinical trials in more countries and regions in South America, Europe, etc
-- Launch trials in Ukraine in August
-
08/03/2021
Direct Biologics
ExoFlo
Two clinical trials evaluating ExoFlo for the treatment of COVID-19-related acute respiratory distress syndrome (ARDS) in inpatient and ICU setting have been completed
-- Commence Phase 1/2 trial for mild-to-moderate COVID-19, called EMOTE COVID-19, later in 2021
-- Start phase 1/2 trial for for Post-Acute COVID-19 Syndrome, dubbed EIPACS, later in 2021
-
08/02/2021
Therapeutic Solutions International, Inc.
(TSOI)
JadiCell
Phase I/IIa trial

-- Data reported on May 21, 2021, showed that JadiCell substantially improved survival in end-stage patients with COVID-19 associated Acute Respiratory Distress Syndrome
--On Jul.27, 2021, preclinical data was reported, suggesting efficacy of JadiCell in animal model resembling COVID-19 Delta Variant associated lung pathology
Conducting Phase III pivotal trial
-
08/01/2021
BetterLife Pharma Inc.
(BETRF.OB)
AP-003
AP-003 given clearance in Chile to enter into phase I/II trial (IN2COVID )
IN2COVID trial set to start in early August
-
08/01/2021
Revive Therapeutics Ltd.
(RVVTF.OB)
Bucillamine
Phase 3 trial in mild to moderate COVID-19.
-- The next independent Data and Safety Monitoring Board review of the study in Q3, 2021
-- Enrollment in phase 3 trial to be completed in Q3, 2021
-
07/31/2021
Todos Medical, Ltd.
Tollovir
Phase 2/3 trials of Tollovir for the treatment of non-hospitalized and hospitalized COVID-19 patients to begin in India
-- Enrollment for both trials to begin in Q3, 2021, with data expected in 4Q, 2021
-- Pivotal trial to begin in 4Q, 2021
NLC Pharma
07/31/2021
Augmenta Bioworks
AUG-3387
In vivo preclinical study

--Data released on Jul.29, 2021, showed AUG-3387 can neutralize SARS-CoV-2 Delta Variant in infective assays
-- In vivo preclinical efficacy studies to be completed in the coming weeks

-- Toxicology studies to start by the end of 2021
TFF Pharmaceuticals Inc. (TFFP)
07/31/2021

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Spirit Airlines has canceled or delayed hundreds of flights following significant operational challenges. The low-cost carrier blamed weather, staffing shortages, and system outages for the issues that caused thousands of passengers stranded in the airports. General Motors Co. (GM) said its second-quarter results were better than originally expected due to strong pricing and demand, record GM Financial results and improved near-term production from the pull forward of semiconductors from the third quarter. Based on first-half performance and expectations... PepsiCo, Inc. (PEP) has reached an agreement with private equity firm PAI Partners to sell Tropicana, Naked and other select juice brands across North America. The agreement also includes an irrevocable option to sell certain juice businesses in Europe. The combined pre-tax cash proceeds will be approximately...